You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
547 Reprogramming of type I interferon-responding tumor-reactive T lymphocytes associates with improved outcomes to neoadjuvant doublet immunotherapy in HNSCC

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023252015
Dec 202361013
Jan 20241805
Feb 20244202
Mar 20242601
Apr 20244201
May 20242201
Jun 20241601
Jul 20241003
Aug 20241801
Sep 20243605
Oct 202450010
Nov 20242402
Dec 20241203
Jan 20253207
Feb 2025404
Mar 2025005
Apr 2025103
May 2025103
Jun 2025002
Total667087